Related Experiment Videos
Monocyte chemoattractant protein-1 and coronary artery disease
Uichi Ikeda1, Keiji Matsui, Yoshiaki Murakami
1Division of Cardiovascular Medicine, Jichi Medical School, Tochigi, Japan. uikeda@jichi.ac.jp
Insights
Monocyte chemoattractant protein-1 (MCP-1) drives atherosclerosis by recruiting monocytes to form plaques. Targeting MCP-1 may prevent plaque formation and reduce heart attack risk.
Area of Science:
- Cardiology
- Immunology
- Vascular Biology
Background:
- Atherosclerosis is increasingly recognized as a chronic inflammatory disease.
- Monocyte chemoattractant protein-1 (MCP-1) is a key chemokine in monocyte recruitment and activation.
- MCP-1 is implicated in the development and progression of atherosclerotic lesions.
Purpose of the Study:
- To explore the role of MCP-1 in atherosclerosis.
- To investigate MCP-1's involvement in plaque vulnerability and restenosis.
- To assess the therapeutic potential of targeting MCP-1 for atherosclerosis.
Main Methods:
- Detection of enhanced MCP-1 expression in macrophages, endothelial cells, and vascular smooth muscle cells within atheromatous plaques.
- Analysis of circulating MCP-1 levels in patients with different forms of coronary artery disease.
- Observation of MCP-1 production and macrophage accumulation post-coronary interventions.
Main Results:
- Elevated MCP-1 expression is found in key cellular components of atherosclerotic plaques.
- Circulating MCP-1 levels are higher in acute myocardial infarction and unstable angina patients compared to stable angina.
- MCP-1 production and macrophage infiltration occur after coronary angioplasty and grafting, correlating with restenosis.
Conclusions:
- MCP-1 plays a critical role in monocyte recruitment, macrophage activation, and atherosclerotic plaque development.
- MCP-1 is associated with plaque vulnerability and the formation of restenotic lesions after interventions.
- Targeting MCP-1 therapeutically offers a promising strategy for preventing atherosclerosis and myocardial infarction.
Abstract:
The designation of atherosclerosis as a chronic inflammatory process represents an exciting and logical paradigm shift for cardiologists. Monocyte chemoattractant protein-1 (MCP-1) plays an important role in the recruitment and activation of monocytes and thus in the development of atherosclerosis. Enhanced MCP-1 expression has been detected in macrophages, endothelial cells, and vascular smooth muscle cells in the atheromatous plaque. Activation of macrophages by MCP-1 also appears to be involved in the vulnerability of the plaque. Indeed, circulating MCP-1 levels are elevated in patients with acute myocardial infarction and in those with unstable angina, but not in patients with stable angina. Production of MCP-1 and macrophage accumulation are also observed after coronary angioplasty or grafting, indicating that MCP-1 expression may be related not only to instability of atheromatous plaques, but also to the formation of restenotic lesions. The development of therapeutic drugs for atherosclerosis targeted specially against MCP-1 may be useful in the prevention of plaque formation and future myocardial infarction.